ÂÜÀòÂÒÂ×

Michael H. Davidson, M.D., FACC, FNLA, joined as the Non-Executive Director in January 2021.

Dr. Davidson is Professor of Medicine and Director of the Lipid Clinic at the University of Chicago. He also serves as chief executive officer of NewAmsterdam Pharma. Dr. Davidson is a leading expert in the field of lipidology. He has conducted over 1,000 clinical trials, published more than 350 medical journal articles, and written three books on lipidology. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson founded the Chicago Center for Clinical Research, which became the largest investigator site in the USA and was acquired by Pharmaceutical Product Development in 1996. Additionally, he founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca in 2013 for $440 million, and most recently, he was founding CEO/CSO of Corvidia Therapeutics, which was acquired by Novo Nordisk for up to $2.1bn in 2020. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology. He was president (2010-2011) of the National Lipid Association, named as one of The Best Doctors in America for the past 15 years, and 'Father of the Year' by the American Diabetes Association, 2010.